Grupo para la caracterización molecular de las neoplasias hematológicas
Princess Margaret Hospital
Christchurch, Nueva ZelandaPublicaciones en colaboración con investigadores/as de Princess Margaret Hospital (5)
2016
-
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low‐dose dexamethasone versus high‐dose dexamethasone in refractory or relapsed and refractory multiple myeloma
Haematologica, Vol. 101, Núm. 7, pp. 872-878
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
2015
-
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Haematologica, Vol. 100, Núm. 10, pp. 1327-1333
-
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma
Haematologica, Vol. 100, Núm. 10, pp. 1334-1339
2013
-
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial
The Lancet Oncology, Vol. 14, Núm. 11, pp. 1055-1066